Human neutrophil peptide in lung chronic allograft dysfunction

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Context: Our previous case-control study identified human neutrophil peptide (HNP) as a potential biomarker for bronchiolitis obliterans syndrome (BOS) in lung transplant recipients. Objective: To prospectively validate HNP as a biomarker for BOS. Materials and methods: HNP was measured by ELISA in bronchoalveolar lavage (BAL) fluid in lung transplant recipients. Results: The first HNP measurement after reaching baseline pulmonary function was predictive of developing BOS ≥2 (p=0.0419). HNP remained elevated in those that developed BOS. The effect of potential confounders did not significantly impact BOS-free survival time. Conclusion: HNP levels are elevated early and persistently in those that develop BOS.

Original languageEnglish (US)
Pages (from-to)663-669
Number of pages7
JournalBiomarkers
Volume16
Issue number8
DOIs
StatePublished - Dec 2011

Bibliographical note

Funding Information:
This work was supported by the National Institutes of Health [Grants HL080041, HL07741] Work performed at the University of Minnesota.

Keywords

  • Biomarkers
  • Lung transplant
  • Rejection

Fingerprint Dive into the research topics of 'Human neutrophil peptide in lung chronic allograft dysfunction'. Together they form a unique fingerprint.

Cite this